Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of apremilast in pediatric moderate-to-severe plaque psoriasis
MOH_2019-08-15_007348Phase 3Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Apremilast with Placebo (2 arms). Primary endpoint: Clinical efficacy of apremilast versus placebo. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2019-08-15_007348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-15_007348.